RMD

• The Board approved Carol Burt as lead director, effective November 15, 2026; she has served on the Board since 2013 and chairs the Nominating and Governance Committee.
• Taylor's retirement is not due to any disagreement with ResMed on operations, policies, or practices.
• ResMed dismissed KPMG as its independent registered public accounting firm on August 13, 2026, and appointed PricewaterhouseCoopers LLP for fiscal year ending June 30, 2027.
• KPMG's reports for fiscal years 2025 and 2026 contained no adverse opinion or qualification, and there were no disagreements or reportable events.

4.01 Changes in Registrant's Certifying Accountant · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Q4 GAAP diluted EPS rose 2% to $2.64; non-GAAP diluted EPS rose 16% to $2.95.
• FY2026 revenue grew 10% to $5.653 billion; GAAP diluted EPS was $10.43, non-GAAP $11.17.
• Board declared quarterly dividend of $0.66 per share, a 10% increase, payable September 24, 2026.
• Company guides to returning over $1.85 billion to shareholders in FY2027 via buybacks and dividends.

2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• ResMed entered a definitive agreement on June 30, 2026, to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in an all-cash transaction.
• MatrixCare represented approximately $220 million of revenue and approximately $55 million of non-GAAP operating profit in fiscal year 2026.
• ResMed intends to use net proceeds for shareholder returns, including an accelerated share repurchase program, and general corporate purposes.
• ResMed reiterated its full-year fiscal 2026 outlook for non-GAAP gross margin, SG&A, R&D, and tax rate, and will provide fiscal 2027 outlook on August 6, 2026.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• GAAP diluted EPS was $2.74; non-GAAP diluted EPS was $2.86, up 21% year-over-year.
• GAAP gross margin was 62.2%, up 290 basis points; non-GAAP gross margin was 62.8%, up 290 basis points.
• Operating cash flow was $554 million; $262 million returned to shareholders via dividends and share repurchases.
• Board declared quarterly cash dividend of $0.60 per share, record date May 14, 2026, payable June 18, 2026.

2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• Sandercock will become Special Advisor to CEO Mick Farrell through December 31, 2026, and continue in a consulting role through December 31, 2027.
• Aaron Bloomer, age 40, will become CFO, Principal Financial Officer, and Principal Accounting Officer effective May 4, 2026.
• Bloomer's compensation includes an annual base salary of $725,000, a sign-on bonus of $150,000, a short-term incentive target of 80% of base salary, and a long-term performance equity grant of $3,300,000.
• Sandercock's retirement was not due to any disagreement with the company on operations, policies, or practices.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits

• Gross margin was 61.8% (up 320 bps); non-GAAP gross margin was 62.3% (up 310 bps).
• Diluted EPS was $2.68; non-GAAP diluted EPS was $2.81, up 16% year-over-year.
• Operating cash flow was $340 million for the quarter.
• Board declared quarterly cash dividend of $0.60 per share, record date February 12, 2026, payable March 19, 2026.

2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• Richard Sulpizio's term as director expired on November 19, 2025, at the conclusion of the Annual Meeting, as he did not seek re-election.
• Stockholders elected eleven directors to serve until the 2026 annual meeting.
• Stockholders approved amendments to the 2009 Incentive Award Plan and the 2018 Employee Stock Purchase Plan, increasing reserved shares by 2.4 million and 3 million respectively.
• Stockholders ratified KPMG LLP as independent auditor and approved say-on-pay.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• GAAP gross margin was 61.5%, up 290 basis points; non-GAAP gross margin was 62.0%, up 280 basis points.
• GAAP diluted EPS was $2.37, up 12%; non-GAAP diluted EPS was $2.55, up 16%.
• Operating cash flow was $457 million for the quarter.
• Board declared a quarterly cash dividend of $0.60 per share, payable December 18, 2025, with record date November 13, 2025.

2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits